Previous Close | 0.0112 |
Open | 0.0112 |
Bid | 0.0112 x 0 |
Ask | 0.0200 x 0 |
Day's Range | 0.0112 - 0.0112 |
52 Week Range | 0.0035 - 0.0400 |
Volume | |
Avg. Volume | 1,339 |
Market Cap | 5.416M |
Beta (5Y Monthly) | 0.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Toronto, Ontario--(Newsfile Corp. - September 26, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by its principal regulator, the British Columbia Securities Commission (the "BCSC"), under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). The Company announced on August 14, 2024 (the "Default Announcement"), that it expecte
Toronto, Ontario--(Newsfile Corp. - September 20, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its non-brokered private placement offering (the "Offering") of units ("Units") as previously announced on August 23, 2024. In connection with the closing of the First Tranche, the Company Issued 22,000,000 Units at a price of $0.011 per Unit, for total gross ...
Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that further to its release issued on August 14, 2024 in respect of its application to the British Columbia Securities Commission (the "BCSC") for a management cease trade order (the "MCTO"), that the BCSC has granted the MCTO, pursuant to which the Company will have until October 28, 2024 to file its annual audited ...